vascular tumors can resemble ES and efforts must be made to exclude a diagnosis of epithelioid hemangioendothelioma. In epithelioid hemangioendothelioma, the unique translocation t(1;3)(p36;q25), resulting in the fusion of WWTR1 with CAMTA1I establishes a firm diagnosis (8) .
The reported overall peak incidence of ES is around 35 years of age (9, 10) . Distal-type ES is more frequently diagnosed and tends to affect a younger (20-40 years of age) and more predominantly male population compared to proximal-type ES, which is usually found in an older population (20-65 years of age) (9, 11) . Distaltype ES can present itself as superficial, slow growing painless firm FiGURe 1 | (A,B) Distal-type ES. (A) Low power histology shows a nodule of tumor present in the dermis and subcutis, comprising a large area of central geographic necrosis, surrounded by sheets of relatively uniform polygonal neoplastic cells (hematoxylin and eosin, ×40). Scale bar, 500 μM. (B) At higher power, these are medium-sized, rounded cells, with ovoid vesicular nuclei with even chromatin, and small nucleoli. This example is cellular, but more sparsely cellular neoplasms can appear subtle, and the neoplastic cells may be confused with inflammatory cells. The characteristic necrosis is seen abutting the tumor cells (bottom left of field) (hematoxylin and eosin, ×200). Scale bar, 50 μM. (C,D) Proximal-type ES. (C) At low power, proximal-type ES comprises sheets or lobules of medium-sized to large round cells, and is seen to lack the more defined architecture and geographic central necrosis of the distal-type variant (hematoxylin and eosin, ×40). Scale bar, 20 μM. (D) At higher power, this is characterized by a sheet-like growth of large polygonal cells, often with focal rhabdoid morphology, and which have ovoid vesicular nuclei, prominent large nucleoli, and relatively abundant eosinophilic cytoplasm. The cells are often more pleomorphic than those of the distal-type variant. On morphology alone, these cells are difficult to distinguish from other malignant epithelioid cells, such as those of carcinoma, melanoma, rhabdomyosarcoma, or epithelioid angiosarcoma, and therefore immunohistochemistry is crucial for establishing a correct diagnosis (hematoxylin and eosin, ×200). Scale bar, 50 μM. (e) Distributions of ES subytpes, adapted from the largest series reported by the French Sarcoma Group (9) . (F) Vulnerabilities in the misassembled SWI\SNF complex when SMARCB1 is absent. Using epithelioid sarcoma as well as rhabdoid tumor as a basis for this model of SMARCB1 null tumors, the misassembled SWI/SNF complex has the potential to dysregulate target loci that may be co-regulated by other transcription factors (36, (38) (39) (40) 43 ) and thereby present indirect ways to drug target the misassembled complex.
nodules leading to chronic non-healing ulcers affecting mostly the hands and arms. Distal-type ES can also arise as deep-seated slow growing tumors in the extremities or in the tenosynovial tissues. Proximal-type ES is more often diagnosed as deep infiltrating soft tissue masses affecting axial proximal regions and is thought to be associated with a more aggressive course (6) . Figure 1E illustrates the sites of involvement of disease. In the largest reported cohort, a majority of ES patients (47%) had localized disease at presentation (2) . ES is one of the rare sarcomas that regularly spread to lymph nodes (2, 12, 13) . The course of disease is characterized by multiple local recurrences and eventual metastatic spread in 30-50% of cases with the lungs being the primary site of involvement (11) . It might be said that local recurrence is the gateway to metastasis.
Management and Prognosis
Optimal management of this rare sarcoma remains to be defined. The cornerstone of treatment of localized disease is wide surgical resection (14) . Neo-adjuvant or adjuvant radiation therapy is often administered in an attempt to reduce local relapses (15, 16) . The role of adjuvant chemotherapy is unclear (13, 14, 17, 18) . Despite multimodal management, the relapse rate remains high and recurrences tend to occur many years later following initial therapy. Reported local relapse rates are ~35% (11, 18, 19 (2) . The available literature on palliative chemotherapy in ES is limited to case reports and small retrospectives studies. The most commonly administered chemotherapy regimens are single-agent anthracycline therapy or the combination an anthracycline with ifosfamide (20) . A single group reported activity of a regimen combining gemcitabine with docetaxel, but the experience is limited to a small number of patients (21) . The activity of navelbine was raised in a case report and may warrant further investigation (22) . Partial responses are rare. Most patients achieve stable disease at best with palliative chemotherapy. In one study, tumor regression was only seen in distal-type disease (20) . However, another group reported high-response rates in proximal-type ES using doxorubicin-ifosfamide combination (23) . With the medical evidence being limited to small retrospectives studies, it is difficult to draw definitive conclusions regarding the chemosensitivity of this histological subtype.
Despite the administration of palliative chemotherapy, patients with metastasis have a poor prognosis. The reported median survival is ~52 weeks and the 1-and 5-year survival rates are 46 and 0%, respectively (2, 20) . Therefore, a substantial unmet need exists to improve the medical management of ES patients by establishing novel systemic regimens and exploring novel targeted therapy. In this review, we will summarize our current understanding of the underlying biology of this rare disease by highlighting implicated signaling pathways and potential actionable biomarkers ( Table 1) . In order to establish a roadmap that can be developed toward effective biology-driven therapies, we will highlight therapeutics opportunities and drugs with promising activity.
Cytogenetic Analyses
Cytogenetic analyses were first attempted to better understand the biology of ES (24) (25) (26) (27) (28) (29) . The karyotype analysis on clinical samples or cells lines varied greatly and was mostly done in adult cases. A minority of samples were diploid, some polypoid, while a great majority had complex patterns consisting of multiple numerical and structural rearrangements (see Table 3 ). Pediatric cytogenetic analyses seem to indicate less complex genetic alterations compared to adults and may therefore offer an explanation of their more favorable prognosis (30, 31) . Translocations t(8;22) (q22;q11) in distal-type ES and t(10;22) in proximal-type ES were found (24, 32) . However, compared to other translocation-driven sarcomas, there is no unique identifiable reoccurring cytogenetic pattern in ES. The only identified recurrent breakpoints have been structural rearrangements involving 18q11 and 22q11. The observation that a substantial number of ES had either rearrangements or deletions of 22q led to the hypothesis that this region may contain a tumor suppressor gene (32, 33) . Further studies identified SMARCB1 as being involved in the tumorigenesis of ES (34) .
SMARCB1
The SMARCB1 gene, located at 22q11, codes for BAF47, a core subunit of the SWI/SNF ATP-dependent chromatin remodeling complex and acts as a tumor suppressor gene (35) . Components of the SWI/SNF complex are mutated in 20% of cancers, most notably rhabdoid tumor (36) . This complex regulates genes by enabling the nucleosome to reposition itself in relation to the DNA sequence (37) . Inactivation of SMARCB1 leads to neoplastic transformation by transcriptional deregulation of target genes implicated in regulating genomic stability, cell-cycle progression, and other signaling pathways in cooperation with transcriptional co-regulators (e.g., MyoD, Olig2) (36, 38, 39) .
SMARCB1 was shown to transcriptionally regulate p16INK4a and/or p21 and repress cyclin D1, thereby suppressing E2F activity and its target genes (40) (41) (42) (48) , and to what extent the misassembled complex aberrantly deregulates loci that are not normally associated with the SWI/SNF complex remains to be investigated. Most certainly, the milieu of transcriptional co-regulators in ES will be different than in rhabdoid tumor. Targeting SMARCB1 is complicated by the different mechanisms of loss of expression. IHC studies demonstrated that the loss of expression of SMARCB1 ranges from 85 to 93% of cases (9, 34, 49, 50) . Allelic homozygous deletions varied from 5 to 71%; however, the true value may be ~10% (51-53). Papp et al. identified different mechanisms to explain the loss of expression of SMARCB1: 13% of cases had biallelic deletions, 33% showed single-allelic deletion, and 4% had point mutations (52) . In 59% of cases, both alleles were intact and no cases had promoter hypermethylation nor post-translational modification. The authors went on to show that loss of SMARCB1 protein expression in those cases is due to epigenetic gene silencing by oncomiRs. Three of the overexpressed miRNAs (miR-206, miR-381, and miR-671-5p) could silence the SMARCB1 mRNA expression in cell cultures (54) . The role of oncomiRs was also validated by another group where miR193a-5p could equally inhibit the mRNA expression of SMARCB1 (55) . Beyond targeting the misassembled SWI/SNF complex, transcriptional co-regulators are also theoretical targets ( Figure 1F) . In summary, loss of SMARCB1 has a crucial role in the pathogenesis of ES (along with other signaling pathways) and therefore is an interesting target to pursue for the development of new therapies. Acknowledging that the restoration of SMARCB1 function is likely the primary therapeutic opportunity in ES, in the paragraphs to follow we discuss other therapeutic opportunities 
Pi3K-AKT-mTOR Signaling Pathway
The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway has been studied extensively and is activated in a myriad of cancers. This signaling pathway's signaling regulates cell proliferation, differentiation, cellular metabolism, and cytoskeletal reorganization leading to apoptosis and cancer cell survival (56) . A previous study done on SMARCB1-deficient tumor cells revealed persistent AKT activation (57) . This finding led Imura et al. to further investigate the importance of this signaling pathway in ES (58) . By studying two SMARCB1-deficient cell lines (VAESBJ and Asra-EPS), this group has shown that AKT/mTOR pathway is constitutively hyperactivated. Results demonstrated that silencing mTOR by transfecting cell lines with anti-mTOR-specific siRNAs suppressed cell proliferation. However, inhibition of mTOR with everolimus caused tumor growth delay without shrinkage. Blocking the mTOR signaling pathway with everolimus caused an increase in AKT and ERK activity, which was subsequently shown to be dependent of c-MET activation. Blocking c-MET activation had a variable effect on growth inhibition on studied cell lines. This variability could be partially explained by the degree of loss of PTEN, which is thought to contribute to resistance to c-MET inhibitors through sustained AKT activation upon mTOR blockade. Combining agents to block both AKT and c-MET were more effective in inducing tumor arrest compared to using either one alone. The importance of AKT and c-MET/HGF pathways was also highlighted through immunohistochemical analysis of random clinical samples. The variability of AKT activation and loss of PTEN expression in different cell lines were also confirmed by another group and thought to correlate with sensitivity of rapamycin (59) . This heterogeneity could highlight the complex genetics of the disease as well as the variable importance of PI3K/AKT/mTOR signaling pathway in the tumorigenesis of ES. In vitro sensitivity to mTOR inhibitors is likely an imperfect surrogate for clinical activity. Nonetheless, these preclinical data are interesting and may warrant additional studies before pursuing clinical trials. Resistance to single-agent mTOR inhibitors can not only be a potential issue but can also possibly be overcome by simultaneously targeting other pathways. These findings are consistent with the shortcomings of targeting mTOR signaling pathway in general and highlight the importance of patient selection and identification of putative biomarkers (60) .
eGF Pathway
The human epidermal growth factor signaling pathway regroups four distinct receptor tyrosine kinases, HER1 (ErbB-1, EGFR), HER2 (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4) and is implicated in cell proliferation, apoptosis, and angiogenesis (61) . The role of EGFR in malignant transformation of carcinomas has been extensively studied. Recently, EGFR expression was revealed to be present in soft tissue and bone sarcomas (62, 63) . However, subsets of disease demonstrating tyrosine kinase domain mutations were rare (64, 65) . These findings sparked an interest in studying EGFR in ES. Cascio et al. showed that 93% of clinical samples (including distal and proximal-type ES) expressed EGFR by IHC (66) . This high level of expression of EGFR was also corroborated by Xie et al. (59) . Furthermore, Cascio et al. went on to show an absence of EGFR amplification via FISH studies. Sequencing of the EFGR gene tyrosine kinase domain revealed no point mutations, insertions, or deletions. Xie et al. further investigated the role of EGFR pathway in the tumorigenesis of ES. EGF-induction contributes to cell-cycle progression partly through upregulation of cyclin D1. EGFR activation also causes an increase in migration and invasion of ES cells where high levels of expression of MMP2 and MMP9 were found. Next, this group tested whether EGFR inhibition with erlotinib would be a viable therapy. Exposure to erlotinib caused tumor growth delay without causing tumor arrest. An explanation for this incomplete response is given by the cooperation of HGFR/MET pathway with EGFR in sustaining AKT and ERK phosphorylation. Dual inhibition of both those pathways had a synergistic effect in decreasing cell proliferation (44) . Combining inhibition of EGFR pathway with erlotinib and mTOR pathway with rapamycin also proved to be synergistic causing cell-cycle arrest as well as an increase in apoptosis (59) . Targeting solely the EGFR pathway may not translate to a possible clinical benefit. However, combined inhibition of EFGR with either mTOR or HGFR\MET may worth investigating further through preclinical animal studies.
Other Possible Actionable Pathways and Targets
Dysadherin is a cancer-associated cell membrane glycoprotein shown to downregulate E-cadherin cell-mediated adhesion and to promote metastasis (67) . Dysadherin contributes to metastatic progression through autocrine activation of CCL2 expression in part through activation of the nuclear factor-kappaB pathway (68) . Dysadherin also has the ability to attribute stem-cell like properties to cancer cells (68, 69) . Higher mRNA expression levels of dysadherin were documented in cell lines derived from proximal-type ES compared to distal-type ES (70) . This difference in expression in levels of dysadherin may offer a possible explanation to the poor prognosis associated with proximal-type ES. Interestingly, in breast cancer cell lines, dysadherin overexpression was shown to possibly enhance AKT activation. Subsequently, inhibiting AKT reduced dysadherin's ability to promote cell mobility and tumor cell invasion (71) . Targeting dysadherin could be potentially exploited to treat ES, but further work is needed. Agonists of the CCL2 receptor, CCR2, such as PF-04634817, may be one area to begin investigation.
The role of Wnt/β-catenin signaling pathway in cancer is well documented. APC deficiency or β-catenin mutations preventing its degradation lead to constitutive activation of β-catenin signaling, which in turn contribute to stem-cell renewal and proliferation (72) . In ES, IHC studies revealed low expressions of nuclear β-catenin (73) . Furthermore, no β-catenin gene mutations were found (74) . Therefore, the proliferative abilities of ES cells are probably related to other mechanisms than Wnt/β-catenin signaling pathway. This finding is in contradistinction to the β-catenin activation seen in rhabdoid tumor (39) . Interestingly, IHC studies identified a complete loss of E-cadherin (70, 73) . E-cadherin is a calcium-dependent glycoprotein responsible for cell-cell adhesion (75) . E-cadherin/β-catenin protein complexes have an active role in epithelial-to-mesenchymal transition (EMT), an important mechanism for the subsequent development of metastasis (76, 77) . Further studies are needed to elucidate the importance of loss of adhesion molecules in tumor progression in ES.
CA125 was first identified and used as a serum marker for epithelial ovarian carcinoma (78) . IHC studies revealed high positivity and specificity of CA125 in ES compared to other sarcomas (79) . High expressions of the MUC16 gene were identified by RT-PCR in ES cell lines. Serum levels of CA125 also seem to correlate with disease progression (80) . Measuring CA125 serum levels is well-established and routinely available and could potentially be useful in monitoring disease status and evaluating response to therapy. Targeted immune strategies toward CA125 and MUC16 are active areas of research in ovarian cancer and any potential breakthroughs could possibly be applicable in treating ES (81, 82) .
Tyrosine Kinase inhibitors
As stated previously, chemotherapy has a limited role in the management of ES. Early studies explored the reasons underlying chemotherapy resistance. A study of the SARCCR2 cell line showed overexpression of P-glycoprotein, an ATP-binding cassette (ABC) chemotherapy export pump. Using verapamil and cyclosporine A to reverse multidrug resistance, the authors showed increased sensitivity to doxorubicin and vincristine (83) . For the GRU cell line, expression of P-glycoprotein and MRP could also be observed (84) . However, one study identified an absence of expression of P-glycoprotein and MRP in the ES-OMC-MN and SFT-8606 cell lines (85) . In contradistinction, these studies demonstrated the presence of lung resistant protein (LRP), which mediates multidrug resistance (MDR). Results showed that reversing MDR with cyclosporin A increased sensitivity to actinomycin D, vincristine, and adriamycin. The use of tyrosine kinase inhibitors, the newest ABC inhibitors, to reverse multidrug resistance remains unexplored and may potentially enhance the efficacy of chemotherapy in ES.
The medical evidence for the utility of tyrosine kinase inhibitors impacting ES is scarce. To our knowledge, only one case was reported in the medical literature. Sunitinib showed reasonable disease stabilization in a patient with metastatic ES (86) . The underlying reasons why sunitinib was active in this patient are unknown and cannot be explained with what is currently known about the biology of this disease. Pazopanib, a recent oral tyrosine kinase inhibitor approved for the treatment of soft tissue sarcoma (87), is worth investigating prospectively as its activity is similar to sunitinib. Work is still needed in mapping out active signaling pathways and identifying actionable tyrosine kinase domain mutations. Polykinase inhibitors remain therefore greatly unexplored in the management of ES and may one day improve outcome.
Future Perspectives
Researching and developing new treatment strategies in rare cancers is a challenge, but possible with technology and resources available today and regulatory agency incentives (88) . ES is a perfect model to envision what personalized medicine promises for the future. The intent of this review was to draw a roadmap to develop efficient biology-driven therapy. Achieving this will start with the selection of representative cell lines and mouse models of ES (Available cell lines and potential actionable targets are summarized in Tables 2 and 3). Many of the potential targets highlighted in this article were based on IHC-expression or reverse-transcriptase PCR studies. DNA deep-sequencing projects may demonstrate underlying genomic amplification and mutations that can be targeted. Partnership with pharmaceutical companies would allow screening of thousands of compounds on selected cell lines presenting mutations or other actionable targets. Active drugs may then undergo preclinical testing. Those most promising can be prioritized for clinical trials. Drugs being developed in other cancers that share common signaling pathways aberrations with ES may also prove to be useful. It is possible to perform basket trials in rare cancers, and this could be a way of evaluating novel agents in this extremely rare disease. On the way of developing new therapies, possible pitfalls can be expected. As demonstrated on ES cell line models, targeting a single signaling pathway may be insufficient. The complexity of the genetic landscape and the crosstalk between multiple signaling pathways contribute to resistance. This can be overcome by targeting multiple signaling pathways simultaneously. Only through international collaboration between pediatric and adult units, we can remain hopeful that targeted and immune therapy will have a major impact in the management of ES in the near future.
